Items Tagged ‘immune response’

March 11th, 2015

Novel PD-1 Inhibitor Opdivo Approved for Treatment of Lung Cancer


The Food and Drug Administration has expanded approval of the PD-1 inhibitor Opdivo® (nivolumab) to include treatment of patients who have metastatic squamous non–small cell lung cancer (NSCLC) that progresses following treatment with platinum-based chemotherapy. Nivolumab belongs to a new class of medicines called PD-1 inhibitors that have generated great excitement for their ability to […]

View full entry

Tags: FDA approval, immune response, Lung Cancer, Lung Cancer - Non-Small Cell, metastatic squamous non-small cell lung cancer, nsclc, opdivo, PD-1 inhibitor, Recurrent Lung Cancer - Non-Small Cell